Abstract
Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity. Conversely, elevated levels of hyaluronic acid (HA) in effusions are sensitive indicators of MM, although specificity is insufficient. We studied whether the cytological diagnosis of MM could be improved by HA analysis. HA was analysed in patients with histologically confirmed MM (n = 162), adenocarcinoma or other malignant tumours (n = 100) and in 90 patients with benign pleural diseases. In 77 out of 162 effusions, all, and in 33 some, cytological criteria of MM were satisfied. The cut-off value of HA showing maximum diagnostic reliability (86%) regarding MM was 30 mg/l (sensitivity 87%, specificity 86%). A HA value of 100 mg/l yielded 39 and 98%, respectively. Seventy three out of 77 patients with cytological findings indicative of MM showed HA levels greater than 30 mg/l as well as 27 of 33 patients with suspicious lesions. These 100 patients were correctly recognised as having MM. The addition of HA analysis to cytology, requiring all or some criteria of MM as positive, increased sensitivity for MM from 48 to 71–91%, whereas specificity only slightly decreased to 94–96%. We conclude that the combined cytological and HA analysis of pleural effusions had the potential to improve the diagnosis of MM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Achatzy R, Beba W, Ritschler R, Worn H, Wahlers B, Macha HN, Morgan JA (1989) The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. Eur J Cardiothorac Surg 3:445–447
Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana–Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153
Antony VB (2003) Immunological mechanisms in pleural disease. Eur Respir J 21:539–544
Atagi S, Ogawara M, Kawahara M, Sakatani M, Furuse K, Ueda E, Yamamoto S (1997) Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 27:293–297
Dahl IM, Solheim OP, Erikstein B, Müller E (1989) A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer 64:68–73
Friman C, Hellström PE, Juvani M, Riska H (1977) Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion. Clin Chim Acta 76:357–361
Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement JP, Housset B (2000) Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 33:405–410
Hillerdal G, Lindqvist U, Engström-Laurent A (1991) Hyaluronan in pleural effusions and in serum. Cancer 67:2410–2414
Martensson G (1990) Diagnosing malignant pleural mesothelioma. Eur Respir J 3:985–986
Martensson G, Thylen A, Lindquist U, Hjerpe A (1994) The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 73:1406–1410
Matzel W (1985) Biochemical and cytological features of diffuse mesotheliomas of the pleura. Arch Geschwulstforsch 55:259–64
Meyer K, Chaffee E (1939) Hyaluronic acid in pleural fluid associated with malignant tumour involving pleura and peritoneum. Pro Soc Exp Biol Med 42:797–800
Parker C, Neville E (2003) Lung cancer * 8: management of malignant mesothelioma 1. Thorax 58:809–813
Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672
Pettersson T, Froseth B, Riska H, Klockars M (1988) Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 94:1037–1039
Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES (1997) The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111:106–109
Spriggs AI, Boddington MM (1994) Atlas of serous fluid cytopathology. A guide to the cells of pleural, pericardial, peritoneal and hydrocele fluid. In: Gresham GA (ed) Current histopathology series, vol 14. Kluwer, Dordrecht (1989)
Stevens MW, Leong AS, Fazzalari NL, Dowling KD, Henderson DW (1992) Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8:333–341
Thylen A, Hjerpe A, Martensson G (2001) Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 92:1224–1230
Welker L, Jörres RA, Costabel U, Magnussen H (2004) Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 24:1000–1006
Conflict of interest statement
L Welker None declared
M Müller None declared
O Holz None declared
E Vollmer None declared
H Magnussen None declared
RA Jörres None declared
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Welker, L., Müller, M., Holz, O. et al. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 450, 455–461 (2007). https://doi.org/10.1007/s00428-007-0375-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-007-0375-x